Trial · NCT02782949

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

NCT02782949, Phase 2, Active not recruiting, National Cancer Institute (NCI); results first posted 2024-03-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia. Trials, record NCT02782949. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02782949

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
NCT number: NCT02782949
Status: Active not recruiting
Phases: Phase 2
Enrollment: 50 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Chronic Atrophic Gastritis, Gastric Carcinoma
Interventions: Curcumin, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment
First posted: 2016-05-26
Last updated: 2026-09-14
Results first posted: 2024-03-05

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa	Baseline up to 6 months	Will be measured by Luminex assay. If the data are not normally distributed, the Wilcoxon Rank-Sum test will be used. The 95% confidence intervals will also be provided.
Secondary	Change in Histology Gastric Score	Baseline up to 6 months	Will compare changes in histology gastric score for curcumin versus placebo. Correa Histopathology Scoring System values according to the histological diagnosis categories Histological diagnosis Correa Histopathology Scores (range) 1. Normal 1 2. non-atrophic gastritis(NAG) 2 3. multifocal atrophic gastritis without intestinal metaplasia (MAG) 3.25-4.00\* 4. IM (intestinal metaplasia) 4.30-5.00\* 5. Dysplasia 5.25-5.75\* 6. Gastric Cancer 6
Secondary	Additional Gastric Mucosal Cytokine/Chemokine Levels (TNFalpha, and IP-10)	Baseline up to 6 months	Will be quantified with Luminex assay. Changes in the concentrations (or categories) will be explored within and between the intervention arms. Fisher's exact tests, Wilcoxon rank sum tests, and two-sample t-tests will be used to assess differences between groups. McNemar's tests, Wilcoxon signed rank tests, and paired sample t-tests will be used to assess differences within each arm. Graphical methods (i.e. boxplots, scatter plots, etc.) will also be used to describe the data.
Secondary	Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage	Baseline up to 6 months	Will be assessed by immunohistochemistry. Fisher's exact tests, Wilcoxon rank sum tests, and two-sample t-tests will be used to assess differences between groups. McNemar's tests, Wilcoxon signed rank tests, and paired sample t-tests will be used to assess differences within each arm. Graphical methods (i.e. boxplots, scatter plots, etc.) will also be used to describe the data.
Other	Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)	At baseline	Will be examined in relation to the outcomes above to further characterize the at-risk population and generate hypotheses for future studies.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa	Baseline up to 6 months	Only 47 evaluable participants.	pg/mL	MEDIAN
SECONDARY	Change in Histology Gastric Score	Baseline up to 6 months	Same populations. A central pathology review of pre-and post-intervention biopsy specimens was performed at the University of Puerto Rico for all study endpoints. Only 47 evaluable participants.	scores on a scale	MEDIAN
SECONDARY	Additional Gastric Mucosal Cytokine/Chemokine Levels (TNFalpha, and IP-10)	Baseline up to 6 months	Only 47 evaluable participants.	pg/mL	MEDIAN
SECONDARY	Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage	Baseline up to 6 months	Only 47 evaluable participants.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)	At baseline

Source ClinicalTrials.gov

Results by group36

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa	Arm I (Curcumin)	Antrum: IL-1beta Difference	0.0	Full Range -4.2 to 10.9	pg/mL
Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa	Arm II (Placebo)	Antrum: IL-1beta Difference	-0.1	Full Range -5.5 to 4.1	pg/mL
Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa	Arm I (Curcumin)	Body: IL-1beta Difference	0.0	Full Range -5.2 to 4.2	pg/mL
Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa	Arm II (Placebo)	Body: IL-1beta Difference	0.1	Full Range -0.8 to 8.6	pg/mL
Change in Histology Gastric Score	Arm I (Curcumin)	Correa Score Difference (Puerto Rico data) central review	0.0	Full Range -2.8 to 3.6	scores on a scale
Change in Histology Gastric Score	Arm II (Placebo)	Correa Score Difference (Puerto Rico data) central review	0.0	Full Range -3.6 to 2.6	scores on a scale
Change in Histology Gastric Score	Arm I (Curcumin)	Correa Score Difference (UAB data)	0.0	Full Range -3.6 to 3.6	scores on a scale
Change in Histology Gastric Score	Arm II (Placebo)	Correa Score Difference (UAB data)	0.0	Full Range -3.9 to 3.5	scores on a scale
Additional Gastric Mucosal Cytokine/Chemokine Levels (TNFalpha, and IP-10)	Arm I (Curcumin)	Antrum: TNF-alpha Difference	-0.1	Full Range -3.8 to 5.7	pg/mL
Additional Gastric Mucosal Cytokine/Chemokine Levels (TNFalpha, and IP-10)	Arm II (Placebo)	Antrum: TNF-alpha Difference	0.0	Full Range -1.8 to 8.7	pg/mL

1 to 10 of 36Source ClinicalTrials.gov

See all 36 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm I (Curcumin)	24
Overall Study	STARTED	Arm II (Placebo)	26
Overall Study	COMPLETED	Arm I (Curcumin)	23
Overall Study	COMPLETED	Arm II (Placebo)	25
Overall Study	NOT COMPLETED	Arm I (Curcumin)	1
Overall Study	NOT COMPLETED	Arm II (Placebo)	1

Source ClinicalTrials.gov

Adverse events80

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Ear pain	Ear and labyrinth disorders	Arm II (Placebo)	0	26	0
other	Ear pain	Ear and labyrinth disorders	Arm I (Curcumin)	1	24	1
other	Cataract	Eye disorders	Arm II (Placebo)	0	26	0
other	Cataract	Eye disorders	Arm I (Curcumin)	1	24	1
other	Abdominal distension	Gastrointestinal disorders	Arm II (Placebo)	1	26	1
other	Abdominal distension	Gastrointestinal disorders	Arm I (Curcumin)	0	24	0
other	Abdominal pain	Gastrointestinal disorders	Arm II (Placebo)	2	26	2
other	Abdominal pain	Gastrointestinal disorders	Arm I (Curcumin)	1	24	1
other	Constipation	Gastrointestinal disorders	Arm II (Placebo)	1	26	1
other	Constipation	Gastrointestinal disorders	Arm I (Curcumin)	0	24	0

1 to 10 of 80Source ClinicalTrials.gov

See all 80 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm II (Placebo)	0	26
Total, all-cause mortality	Arm I (Curcumin)	0	24
Total, other adverse events	Arm II (Placebo)	14	26
Total, other adverse events	Arm I (Curcumin)	12	24
Total, serious adverse events	Arm II (Placebo)	0	26
Total, serious adverse events	Arm I (Curcumin)	0	24

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
39148307	DERIVED	PubMed
42077070	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA015083	Mayo Clinic Comprehensive Cancer Center Support Grant	WILLMAN, CHERYL LYNN	MAYO CLINIC ROCHESTER	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Arm I (Curcumin) vs Arm II (Placebo): deaths from any cause	Trial comparisons
Arm I (Curcumin) vs Arm II (Placebo): serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02782949

GET https://conductscience.org/api/trials/v1/NCT02782949/results?page=2

API reference For AI assistants